User menu

Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials.

Bibliographic reference Camilleri, Michael ; Piessevaux, Hubert ; Yiannakou, Yan ; Tack, Jan ; Kerstens, René ; et. al. Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials.. In: Digestive Diseases and Sciences, Vol. 61, no.8, p. 2357-2372 (2016)
Permanent URL http://hdl.handle.net/2078.1/180356
  1. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther. 2010;31:938–949.
  2. JOHANSON J. F., KRALSTEIN J., Chronic constipation: a survey of the patient perspective : PATIENT PERSPECTIVE ON CONSTIPATION, 10.1111/j.1365-2036.2006.03238.x
  3. Ramkumar Davendra, Rao Satish S.C., Efficacy and Safety of Traditional Medical Therapies for Chronic Constipation: Systematic Review, 10.1111/j.1572-0241.2005.40925.x
  4. Bassotti Gabrio, Slow transit constipation: A functional disorder becomes an enteric neuropathy, 10.3748/wjg.v12.i29.4609
  5. Krishnamurthy Shoba, Schuffler Michael D., Rohrmann Charles A., Pope Charles E., Severe Idiopathic Constipation Is Associated With a Distinctive Abnormality of the Colonic Myenteric Plexus, 10.1016/s0016-5085(85)80128-1
  6. Singh S., Heady S., Coss-Adame E., Rao S. S. C., Clinical utility of colonic manometry in slow transit constipation, 10.1111/nmo.12092
  7. Dinning P. G., Wiklendt L., Maslen L., Patton V., Lewis H., Arkwright J. W., Wattchow D. A., Lubowski D. Z., Costa M., Bampton P. A., Colonic motor abnormalities in slow transit constipation defined by high resolution, fibre-optic manometry, 10.1111/nmo.12502
  8. wattchow d., brookes s., murphy e., carbone s., de fontgalland d., costa m., Regional variation in the neurochemical coding of the myenteric plexus of the human colon and changes in patients with slow transit constipation, 10.1111/j.1365-2982.2008.01165.x
  9. He Chong–Liang, Burgart Larry, Wang Linan, Pemberton John, Young–Fadok Tonia, Szurszewski Joseph, Farrugia Gianrico, Decreased interstitial cell of Cajal volume in patients with slow-transit constipation, 10.1016/s0016-5085(00)70409-4
  10. Johnson David A, Treating Chronic Constipation : How Should We Interpret the Recommendations?, 10.2165/00044011-200626100-00001
  11. Dinning Phil G, Hunt Linda, Patton Vicki, Zhang Teng, Szczesniak Michal, Gebski Val, Jones Mike, Stewart Peter, Lubowski David Z, Cook Ian J, Treatment Efficacy of Sacral Nerve Stimulation in Slow Transit Constipation: A Two-Phase, Double-Blind Randomized Controlled Crossover Study, 10.1038/ajg.2015.101
  12. Corsetti Maura, Tack Jan, New pharmacological treatment options for chronic constipation, 10.1517/14656566.2014.900543
  13. Tonini M., 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors, 10.1111/j.1365-2982.2005.00716.x
  14. De Maeyer J. H., Lefebvre R. A., Schuurkes J. A. J., 5-HT4 receptor agonists: similar but not the same : 5-HT4 receptor agonists: similar but not the same, 10.1111/j.1365-2982.2007.01059.x
  15. Tack J., Camilleri M., Chang L., Chey W. D., Galligan J. J., Lacy B. E., Müller-Lissner S., Quigley E. M. M., Schuurkes J., Maeyer J. H., Stanghellini V., Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders, 10.1111/j.1365-2036.2012.05011.x
  16. Chapman Hugh, Pasternack Michael, The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph, 10.1016/j.ejphar.2006.10.019
  17. European Medicines Agency. Annex I. Summary of product characteristics Resolor. 2014.
  18. Camilleri Michael, Kerstens René, Rykx An, Vandeplassche Lieve, A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation, 10.1056/nejmoa0800670
  19. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L, Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives, 10.1136/gut.2008.162404
  20. QUIGLEY E. M. M., VANDEPLASSCHE L., KERSTENS R., AUSMA J., Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study, 10.1111/j.1365-2036.2008.03884.x
  21. Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil. 2012;24:999-e541.
  22. Piessevaux H., Corazziari E., Rey E., Simren M., Wiechowska-Kozlowska A., Kerstens R., Cools M., Barrett K., Levine A., A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride, 10.1111/nmo.12553
  23. Yiannakou Yan, Piessevaux Hubert, Bouchoucha Michel, Schiefke Ingolf, Filip Rafal, Gabalec Libor, Dina Ion, Stephenson David, Kerstens René, Etherson Kevin, Levine Amy, A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation, 10.1038/ajg.2015.115
  24. Higgins Julian P. T., Thompson Simon G., Quantifying heterogeneity in a meta-analysis, 10.1002/sim.1186
  25. Shin A., Camilleri M., Kolar G., Erwin P., West C. P., Murad M. H., Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation, 10.1111/apt.12571
  26. Tack Jan, Quigley Eamonn, Camilleri Michael, Vandeplassche Lieve, Kerstens René, Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis, 10.1177/2050640612474651
  27. Ke MeiYun, Tack Jan, Quigley Eamonn M M, Zou Duowu, Choi Suck Chei, Leelakusolvong Somchai, Liu Andy, Kim JinYong, Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies, 10.5056/jnm14029
  28. Bharucha A. E., High amplitude propagated contractions : High amplitude propagated contractions, 10.1111/nmo.12019
  29. Bassotti G, Gaburri M, Imbimbo B P, Rossi L, Farroni F, Pelli M A, Morelli A, Colonic mass movements in idiopathic chronic constipation., 10.1136/gut.29.9.1173
  30. Dinning Philip G., Di Lorenzo Carlo, Colonic dysmotility in constipation, 10.1016/j.bpg.2010.12.006
  31. Bouras Ernest P., Camilleri Michael, Burton Duane D., Thomforde George, McKinzie Sanna, Zinsmeister Alan R., Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder, 10.1053/gast.2001.21166
  32. Camilleri Michael, New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety, 10.1155/2011/670484
  33. Sweetser S., Busciglio I. A., Camilleri M., Bharucha A. E., Szarka L. A., Papathanasopoulos A., Burton D. D., Eckert D. J., Zinsmeister A. R., Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects, 10.1152/ajpgi.90558.2008
  34. Videlock Elizabeth J., Cheng Vivian, Cremonini Filippo, Effects of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation: A Meta-analysis, 10.1016/j.cgh.2013.04.032
  35. Manini ML, Camilleri M, Goldberg M, et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil. 2010;22:42–49.
  36. Goldberg M., Li Y.-P., Johanson J. F., Mangel A. W., Kitt M., Beattie D. T., Kersey K., Daniels O., Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study : Clinical trial: efficacy of velusetrag in chronic idiopathic constipation, 10.1111/j.1365-2036.2010.04456.x
  37. camilleri m., vazquez-roque m. i., burton d., ford t., mckinzie s., zinsmeister a. r., druzgala p., Pharmacodynamic effects of a novel prokinetic 5-HT4receptor agonist, ATI-7505, in humans, 10.1111/j.1365-2982.2006.00865.x
  38. Shin Andrea, Acosta Andres, Camilleri Michael, Boldingh Amy, Burton Duane, Ryks Michael, Rhoten Deborah, Zinsmeister Alan R., A Randomized Trial of 5-Hydroxytryptamine4–Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation, 10.1016/j.cgh.2014.08.012
  39. QUIGLEY Eamonn MM, Cisapride: What can we learn from the rise and fall of a prokinetic? : Cisapride; a look back, 10.1111/j.1751-2980.2011.00491.x
  40. Chan Kayi Y., de Vries René, Leijten Frank P.J., Pfannkuche Hans-Juergen, van den Bogaerdt Antoon J., Danser Alexander H.J., MaassenVanDenBrink Antoinette, Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries, 10.1016/j.ejphar.2009.07.010
  41. Mendzelevski Boaz, Ausma Jannie, Chanter Dennis O., Robinson Patricia, Kerstens Rene, Vandeplassche Lieve, Camm John, Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study : Prucalopride thorough QT study in healthy volunteers, 10.1111/j.1365-2125.2011.04088.x
  42. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009;21:1256-e117.